This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Korbelik, M. Articles by Chaplin, D. J. Search for Related Content PubMed PubMed Citation Articles by Korbelik, M. Articles by Chaplin, D. J.

Photofrin Uptake by Murine Macrophages¹

Cancer Imaging [M. K., G. K.] and Medical Biophysics Unit [D. J. C.], British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada V5Z 1L3

The uptake of Photofrin by murine peritoneal macrophages in vivo and in vitro was examined. Cellular Photofrin content was measured either by performing a fluorometric assay or by using ¹⁴C-labeled drug. For comparison, the uptake of Photofrin by murine SCCVII tumor cells (squamous cell carcinoma) was also examined under the same conditions. The data demonstrate that macrophages have a much greater capacity for Photofrin uptake than SCCVII tumor cells. Photofrin contents at 24 h after drug administration (25 mg/kg) measured 420 ± 90 (SD), 74 ± 15, and 15 ± 2 ng/µg of cell protein for peritoneal macrophages, tumor-associated macrophages, and SCCVII tumor cells, respectively. Factors that modify macrophage activity also influence the uptake of the drug by macrophages. The results support the assumption that Photofrin uptake by macrophages is dominated by phagocytosis of highly aggregated components of the drug. In vivo accumulated Photofrin material in peritoneal macrophages, tumor-associated macrophages, and tumor cells has shown very similar in vitro clearance from all three cell types. Only 20–30% of Photofrin was lost from the cells during the initial 24 h, mainly between 1 and 4 h of clearance incubation.

¹ M. K. was supported by Operational Grant 119 (89-1) and Scholarship Grant 163 (89-1) awarded by the British Columbia Health Care Research Foundation.

² To whom requests for reprints should be addressed, at Cancer Imaging, British Columbia Cancer Research Centre, 601 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 1L3.

Received 11/26/90. Accepted 2/13/91.

This article has been cited by other articles:

				S. M. Hahn, M. E. Putt, J. Metz, D. B. Shin, E. Rickter, C. Menon, D. Smith, E. Glatstein, D. L. Fraker, and T. M. Busch Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin. Cancer Res., September 15, 2006; 12(18): 5464 - 5470. [Abstract] [Full Text] [PDF]

				D. I. Fielding, G. A. Buonaccorsi, A. J. MacRobert, A. M. Hanby, M. R. Hetzel, and S. G. Bown Fine-Needle Interstitial Photodynamic Therapy of the Lung Parenchyma: Photosensitizer Distribution and Morphologic Effects of Treatment Chest, February 1, 1999; 115(2): 502 - 510. [Abstract] [Full Text] [PDF]